Uncategorized
Analysis: Eylea, Lucentis less cost-effective than Avastin for treatment of DME
Aflibercept and ranibizumab were less cost-effective than bevacizumab in the treatment of diabetic macular edema, according to a post hoc analysis of data from the Diabetic Retinopathy Clinical Research Network Protocol T trial.“These results highlight the challenges that physicians, patients and policymakers face when safety and efficacy results are at odds with cost-effectiveness results,” the study authors said.